Displaying drugs 801 - 825 of 15699 in total
Interferon alfa-n1
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Haloperidol
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently ... through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and ... [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and …
Sulesomab
Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …
Clobazam
Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others. . Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has...
Approved
Illicit
Matched Description: … , Frisium, Urbanyl, and others. ... children aged two years and older. ... and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Acetohexamide
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Cenegermin
Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563]
While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Rozanolixizumab
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. ... [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Human interferon beta
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and ... [L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Crizanlizumab
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … It was developed by Novartis and was granted FDA approval on November 15, 2019. ... L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and ... Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Relugolix
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and ... [A225761]
Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist ... [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …
Becaplermin
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together...
Approved
Investigational
Matched Description: … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins ... Preparations for Treatment of Wounds and Ulcers …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins ... Preparations for Treatment of Wounds and Ulcers …
Piperaquine
Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative DB11638 as part of...
Approved
Experimental
Investigational
Matched Description: … Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550 ... Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and …
Matched Categories: … artenimol and piperaquine ... arterolane and piperaquine ... artemisinin and piperaquine ... Antiparasitic Products, Insecticides and Repellents …
Matched Categories: … artenimol and piperaquine ... arterolane and piperaquine ... artemisinin and piperaquine ... Antiparasitic Products, Insecticides and Repellents …
Plasminogen
Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Terconazole
Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a triazole ketal derivative. Terconazole was initially approved by the FDA in 1987.[FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels...
Approved
Matched Description: … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels ... of safety, efficacy, and tolerability in clinical trials. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Cetuximab
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Description: … neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with ... EGFR overexpression has been linked to more advanced disease and poor prognosis. ... cells; it is responsible for regulating epithelial tissue development and homeostasis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Casein
Casein allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Fluids and Secretions ... Diet, Food, and Nutrition ... Amino Acids, Peptides, and Proteins …
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009]
Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Chromium nicotinate
Approved
Experimental
Hexachlorophene
A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)
Approved
Withdrawn
Matched Description: … It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders …
Matched Categories: … Phenol and Derivatives ... Antiseptics and Disinfectants …
Matched Categories: … Phenol and Derivatives ... Antiseptics and Disinfectants …
Miltefosine
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of ... It can be administered topically or orally and is only indicated in patients aged 12 years or older. ... first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sacituzumab govitecan
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Commission and Health Canada respectively. ... [L13002, A193674]
Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Antithymocyte immunoglobulin (rabbit)
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Antilymphocyte immunoglobulin (horse)
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that...
Approved
Investigational
Matched Description: … system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and ... currently indicated for the suppression of the immune system to prevent renal transplant rejection and ... Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 801 - 825 of 15699 in total